Given the unmet need in the adjuvant treatment of intermediate-to-high-risk HNSCC patients , it is expected that LUX-Head & Neck 2 will provide new insights into treatment in this setting and might demonstrate the ability of afatinib to significantly improve disease-free survival , compared with placebo .